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by the G-BA. Methods: Oncology medicines with completed EBAs by 01 Jan 2015 
were analysed for i) presence of cross-over in pivotal trials; ii) efficacy results before 
and after cross-over and iii) evidence levels granted by the G-BA (proof, indication 
or hint). Results: Cross-over was frequent in oncology, concerning 14 of 28 EBAs 
(50%). For 6 of the 14 medicines, cross-over could be considered ethically required as 
significant differences in overall survival (OS) were demonstrated prior to cross-over. 
For most medicines, data on OS and progression-free survival were reported after 
cross-over (10/14 and 8/14, respectively). Significant differences in OS post-cross-over 
could only be shown for 2 out of the 8 medicines for which no such differences were 
demonstrated before cross-over. An evidence level of proof was granted by the G-BA 
for 3 out of the 14 medicines, all of which were orphan drugs, but none were granted 
for medicines with ethically required cross-over. ConClusions: The G-BA regards 
evidence standards as only partially fulfilled in cases of ethically required cross-over 
in oncology. Highly efficacious drugs with ethically mandated cross-over are there-
fore systematically disadvantaged with regards to the achievable evidence category, 
indicating a bias against innovation. Medicines with a demonstration of superior effi-
cacy and subsequent ethically justified cross-over deserve an evidence level of proof.
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Qualitative assessmeNt of soCietal PrefereNCes for market aCCess 
of CaNCer Drugs
Pauwels K, Huys I, Casteels M, Simoens S
KU Leuven, Leuven, Belgium
objeCtives: The need and price for cancer drugs will increase while budgets 
are becoming more constrained. Policy makers need to make hard choices about 
which drugs are worthwhile. Inclusion of societal preferences in resource alloca-
tion is emphasized by academic research and policy makers. This study qualita-
tively assesses societal preferences for market access of cancer drugs. Methods: 
Focus group discussions (FGD) with members of the general population in Flanders 
(Belgium) were organized. Participants were recruited through flyers distributed in the 
University Hospitals Leuven and social media. First, the topic of budgetary constraints 
and resource allocation was introduced. Next, introductory statements based on ethi-
cal principles were discussed. Hypothetical scenarios were set up to ask people about 
characteristics of a patient, disease and drug that they would use to prioritize if there 
is only money to use/treat one of them. FGD were led by one researcher, video and 
audio recorded, verbatim transcribed and analyzed using thematic framework analy-
sis. FGD were repeated until data saturation. Participants received a compensation 
of € 20. Results: Three FGD with each six participants were conducted in February 
2015. The median age of participants was 43 years (22-65, N= 18). When participants 
are asked to define criteria they would use to prioritize patients, they mention age and 
life style of a patient and severity of the disease. They prefer to treat the largest patient 
group with the best prognosis. Drugs would be prioritized by participants based on 
the effect on quality of life, side effects and treatment duration. ConClusions: 
Participants would like to maximize the benefits within a restricted budget, but con-
flicts between criteria such as prognosis and severity of disease crop up. Further 
research will quantify the relative importance and the trade-offs between criteria 
that society is willing to make through a discrete choice experiment.
PCN317
PriCe struCture assessmeNt of seleCteD oNCology ProDuCts iN 
ChiNa, taiwaN, south korea, Brazil, aND mexiCo
Napiecek D, Shah S, Ramesh V
Market Access Solutions LLC, Raritan, NJ, USA
objeCtives: To understand the impact of supply chain and healthcare system struc-
ture on public price for oncologics in selected emerging markets. Methods: Review 
of published price data and publicly available information from health authorities, 
WHO websites, peer reviewed and scholarly publications. Primary input from current 
payers and healthcare for validation and gap mitigation. Results: In the selected 
countries, when comparing to the US pharmacy price as benchmark, oral targeted 
oncologics were priced lower than injectable oncologics. Brazil and the Mexican pri-
vate sector saw the largest disparity with difference of approximately 40% between 
orals and injectables. Taiwan had the smallest difference between orals and injecta-
bles with only a 4% difference. China had the highest prices among the selected 
countries. In countries with both a public and private market, the prices in the public 
sector were always lower than those in the private sector. The ex-factory prices in 
the selected countries were much closer, with maximum 16% difference between 
lowest to highest price level. Brazil has the highest ex-factory price for orals with 
72% and China has the highest for injectables with 77%. South Korea had the lowest 
ex-factory and pharmacy prices for both orals and injectables. ConClusions: The 
combination of no reimbursement, a regionalized approach to pricing, and a com-
plex distribution chain has led to highest mark-ups at pharmacy level price in China 
among the selected countries despite having similar ex-factory prices. Due to tougher 
price negotiations in the public sectors, targeted oncology products enter the Brazil 
and Mexico markets in the private sector first then enter the public market which 
allows for greater the average price differential between public and private sectors. 
With universal healthcare systems in South Korea and Taiwan and international price 
referencing the price differences between orals and injectables and the mark up from 
ex-factory to pharmacy purchasing price is negligible.
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imPaCt oN time gaP BetweeN aPProval aND reimBursemeNt of target 
theraPy to aDvaNCeD ColoreCtal CaNCer
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objeCtives: Three target therapies for advance CRC had been approved by TFDA 
since 2005; only two are under reimbursement now. Long reimbursement process 
had prevented advanced CRC patients from prescribing target therapy. This study 
is to use Cetuximab, the first reimbursed target therapy to evaluate the impact of 
min vs. 23.3 min, -65%). ConClusions: Time savings associated with Dmab SC 
injection were seen for all outcome measures. Opting for Dmab SC injection instead 
of Zol IV infusion should free up the hospital capacity to treat more patients, and 
decrease patients’ treatment burden in Italy.
PCN313
DesCriPtioN of BaseliNe CharaCteristiCs of PatieNts ProviDeD 
CaNCer Care withiN a Novel CommerCial health PlaN CaNCer Care 
Quality Program iN the first year
Tunceli O1, Willey V1, Quimbo R1, Mack M1, Malin J2
1HealthCore Inc., Wilmington, DE, USA, 2Anthem, Woodland Hills, CA, USA
objeCtives: The HIRE – Oncology contains clinical oncology data captured as part 
of the Cancer Care Quality Program (CCQP), a novel program by Anthem health 
plans designed to align reimbursement with evidence-based, cost-effective oncol-
ogy treatment, that is integrated with administrative claims data in the HealthCore 
Integrated Research Database (HIRD). This study updates prior research describing 
the baseline characteristics of patients within oncology practices participating in the 
CCQP. Methods: Breast, colon, and lung cancer patients from HIRE-Oncology were 
identified between 6/23/2014 and 3/6/2015 (Intake Period). Patients were character-
ized based on the earliest request to utilize chemotherapy and/or supportive care 
medications (Index Date) during the Intake Period; analyses included patients with ≥ 6 
months of continuous pre-index eligibility. Baseline characteristics were stratified by 
cancer type/stage and included: pathology, biomarkers, health care costs, and Deyo-
Charlson Index (DCI). Results: A total of 2,206 breast, 554 colon, and 796 lung cancer 
patients were identified with mean(SD) ages and DCI’s of 64(10), 56(10), and 61(9) and 
5.6(3.2), 7.6(2.6), and 7.8(2.8), respectively. Stage distributions indicated the greatest 
prevalence with stage IV disease: 36%, 73%, and 74% among breast, colon, and lung 
cancers patients. Pathology results among lung cancer patients demonstrated 78% 
and 22% with non-small cell and small cell cancers, respectively. 36% of breast cancer 
patients were HER2 positive, 34% of lung cancer patients were detected with EGFR 
mutation, and 32% of colon cancer patients were detected with KRAS mutation among 
those reporting test results. Across all stages, total all-cause mean (SD) baseline health 
care costs were $51,430($58,567), $67,760($59,064), and $59,789($55,846) among breast, 
colon, and lung cancer patients, respectively. ConClusions: This updated analysis 
provides valuable initial insight into the demographic and clinical characteristics of 
patients within participating practices during the first year. HIRE-Oncology provides 
a comprehensive picture for commercially-insured oncology patients and baseline 
data for future program evaluation.
PCN314
oNCologist suPPort for ameriCaN soCiety of CliNiCal oNCology 
(asCo) CoNsoliDateD PaymeNts for CaNCer Care maNagemeNt iN the 
uNiteD states (us)
Narayanan S, Hautamaki E
Ipsos Healthcare, Washington, DC, USA
objeCtives: To assess physician support of the 2014 ASCO payment reform pro-
posal, focusing on four components: 1) new patient payments- single payment for 
any new patient until treatment begins; 2) treatment month payments-each month 
the patient is treated; 3) active monitoring month payments-during months when 
the patient is not actively treated but receiving care and support; 4) transition of 
treatment payments-for a change in patient status during a month. Methods: 
Medical-oncologists and hematologist/oncologists across the US, practicing for at 
least 2yrs and managing at least 20 patients, were randomly sampled to participate 
in a cross-sectional survey via a panel. Results: 231 physicians participated (87% 
physicians, 13% medical directors; 67.5% hematologist/oncologists, 32.5% medical-
oncologists). Mean practice duration:15yrs; 53% practice in an academic/community/
Veteran’s facility and 47% in group/solo private practice; geographic distribution: 
South:32%/Northeast:29%/Midwest:23%/West:17%. Only 7% rated the reimburse-
ment climate as “excellent” (good:32%/satisfactory:42%/not very good:20%/bad:2%); 
18% rated the financial status of their cancer program as “excellent” (good:41%/sat-
isfactory:33%/not very good:7%/bad:< 1%). Physicians reporting that they “strongly” 
or “somewhat” support the components of the 2014 ASCO proposal: 1) new patient 
payments:47%; 2) treatment month payments:57%; 3) active monitoring month pay-
ments:55%; and 4) transition of treatment payments:54%. Physician rating of “strong/
somewhat support” based on perception of reimbursement climate (excellent/good 
vs. satisfactory/not very good/bad): 1) new patient payments:55%/42%; 2) treatment 
month payments:66%/51%; 3) active monitoring month payments:65%/48%; 4) 
transition of treatment payments:61%/50%. “Strong/somewhat” support based on 
perception of financial status of their cancer program (excellent/good vs. satisfac-
tory/not very good/bad): 1) new patient payments:49%/44%; 2) treatment month 
payments:61%/52%; 3) active monitoring month payments:60%/47%; 4) transition of 
treatment payments:59%/47%. ConClusions: About half of the physicians in the 
study supported the components of ASCO’s 2014 proposed payment reform, espe-
cially if they already considered the current reimbursement climate and financial 
status of the cancer program to be positive.
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g-Ba Does Not aDjust eviDeNCe reQuiremeNts iN early BeNefit 
assessmeNt iN Cases of Pre-DefiNeD, effiCaCy-BaseD Cross-over 
DeCisioNs iN oNCology trials
Isbary G1, Staab TR1, Amelung VE2, Dintsios C3, Ruof J1
1Roche Pharma, Grenzach-Wyhlen, Germany, 2Institute for Applied Health Services Research, 
Berlin, Germany, 3Bayer Vital GmbH, Leverkusen, Germany
objeCtives: In Germany, an early benefit assessment (EBA) by the Federal Joint 
Committee (G-BA) is compulsory for all new drugs. Pre-defined treatment switching, 
often called ‘cross-over’, is often seen in oncology clinical trials. Cross-over is usu-
ally implemented for ethical reasons, i.e. to ensure access to a beneficial treatment 
for all patients, but may confound data analysis by improving efficacy in the con-
trol arms. We aimed to analyse the impact of cross-over on evidence levels granted 
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objeCtives: Accelerated approval pathways can shorten time to market for thera-
pies treating diseases, particularly those with significant morbidity and mortality 
and few effective alternatives. However, little is known about payers’ reactions to 
submissions based on a Phase 2, single-arm trial. This study aimed to identify mar-
ket access challenges for products with accelerated marketing authorization based 
on this limited data package. Methods: Oncology products receiving European 
marketing authorization since 2012 based on a Phase 2, single-arm study were 
identified and the associated EPARs and HTA submissions in France, Germany and 
the UK (NICE) reviewed. Results: Six products were identified (Adcetris, Bosulif, 
Erivedge, Iclusig, Imbruvica, and Zydelig); four had orphan designation. No pivotal 
trials included survival as the primary endpoint, none reported HRQL and no com-
parative data were cited in the regulatory packages. Only one product was reviewed 
by NICE (England) and was not recommended (another did not submit). All six G-BA 
(Germany) reviews resulted in either additional benefit not proven, not quantifiable 
(or minor in one subgroup). In France, the ASMR ratings ranged from III to V (mod-
erate, to no improvement compared with existing treatments). Common themes 
identified which could be addressed by additional evidence generation included: (1) 
clarity on the target patient population and unmet need; (2) establishing the cur-
rent standard of care and positioning within the treatment pathway; (3) determin-
ing relative efficacy given the focus on survival benefit and the increasing weight 
of additional value drivers. ConClusions: Although marketing authorization is 
granted, products supported by Phase 2, single-arm trial data face significant HTA 
challenges; payers are being asked to make decisions based on limited data. Some 
evidence gaps can be addressed with additional evidence generated alongside the 
pivotal trial. However, uncertainty about a product’s value may result in poor HTA 
outcomes, and a poor position from which to negotiate price.
PCN323
Does BuDget imPaCt affeCt reimBursemeNt DeCisioNs maDe By the 
CaNCer Drugs fuND iN eNglaND?
Stewart G, Kusel J, Montgomery S
Costello Medical Consulting Ltd, Cambridge, UK
objeCtives: The Cancer Drugs Fund (CDF) in England has an annual budget of 
£280 million to fund cancer drugs on the NHS that were not assessed by or were 
rejected by NICE. In 2014, drugs on the CDF were re-assessed based on criteria 
including cost per patient and 16 were removed from the list. Previous analy-
sis on a sub-set of the drugs that were re-assessed indicated that drugs with a 
higher budget impact might be more likely to be rejected by the CDF (presented 
at HTAi 2015). We aimed to expand the analysis to all those re-appraised by 
the CDF, to investigate whether this trends holds when a larger sample size is 
used. Methods: Using the cost per cycle, cycle length and median duration of 
treatment extracted from the CDF decision summaries, the cost per patient was 
calculated for every drug assessed in 2014. The budget impact of those drugs that 
had previously been reimbursed by the CDF was calculated based on the number of 
notifications that the CDF received in 2014. A point-biserial correlation coefficient 
(rpb) was used to assess whether cost per patient and total budget impact were 
correlated with the CDF reimbursement decision. Results: Investigation of the 
larger sample set confirmed the initial results of the previous analysis and deter-
mined that there was a positive correlation for cancer drugs with a higher cost per 
patient to be included in the CDF (rpb= 0.643); this is most likely due to the superior 
clinical evidence. The budget impact was found to have little influence on the CDF 
reimbursement decision in this larger sample size (rpb= 0.105). ConClusions: 
Although the CDF’s new criteria for reimbursement do involve an evaluation of 
the cost of each drug, it seems that neither the cost per patient nor the overall 
budget impact greatly influences their decisions.
PCN324
PatieNt rePorteD outComes (Pro) iN PostProgressioN oNCology: 
imPliCatioNs iN health teChNology assessmeNts (hta) & Payer 
DeCisioN makiNg
Hogue S1, Brogan AP1, DeMuro C1, D’Alessio D2, Bal V2
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Novartis Pharmaceuticals Corporation, 
East Hanover, NJ, USA
objeCtives: To assess the impact of PRO data collected after clinical progression 
(i.e., postprogression) on payer decision making in oncology. Methods: One-on-
one interviews were conducted with 16 payers and payer advisors from 14 countries 
in 2014. An online assessment was conducted (December 8, 2014, to March 4, 2015) 
with 20 completed surveys (China, France, Germany, Spain, Taiwan, the UK, the US) 
and 7 partially completed surveys (Australia, South Korea, the US) by payers from 
the RTI Health Solutions Global Payer Advisory Panel. Results: PRO data are com-
monly collected during trials; however, collection of PRO data postprogression is 
less common. When asked about the value of collecting PRO data postprogression, 
payers indicated that they consider this particularly important in cancer types with 
relatively long survival and those that involve palliative and/or long-term care. All 
payers in the one-on-one interviews advised collecting postprogression PRO data in 
both the control and comparator arms. Eleven of the 16 respondents in the one-on-
one interviews indicated that it is worthwhile to collect PRO data postprogression 
and that positive PRO data may support continued therapy, even if the tumor is pro-
gressing. Results from the online assessment indicated that payers outside the US 
considered postprogression PRO data more useful than US payers did. When queried 
about specific types of postprogression data, payers generally thought that all types 
of PRO data examined (stability of disease, improvement in health-related quality 
of life, improvement in symptom severity or frequency, improvement in functional 
status, slower rate of functional deterioration compared to control/comparator arm) 
were important to decision making. Payers generally deferred to clinical experts on 
the length and frequency of postprogression PRO data collection. ConClusions: 
PRO data provide compelling evidence even after tumors have progressed clinically 
and may help differentiate products, especially in situations where therapies do not 
provide significant survival benefits.
time gap from TFDA approval to reimbursement on mortality for advanced CRC 
patients. Methods: The data was form 2 million sampling reimbursement data 
set of Taiwan’s National Health Insurance Research Database (NHIRD) and diseased 
stage was derived from the Taiwan Cancer Registry (TCR) between 2007 and 2011. 
Diseased stage diagnosed for the first time ever of CRC patients was recorded in TCR. 
Patients’ survival data and prescription time of target therapy were derived. Fisher 
exact test was used for the comparisons of frequencies; log rank was used survival 
comparisons; and hazard ratio was derived using both Cox regression with time 
and time independent analysis. Results: 364 staged 4 CRC patients were derived 
and enrolled into the analysis. There were 11 patients diagnosed with CRC before 
the target therapy was approved for reimbursement, whereas 353 were diagnosed 
after. 70 of them were prescribed target therapy during the disease treatment period. 
Median survival years for those who were prescribed target therapy was 2.6 as com-
pared to 1.2 without. There was a statistical significant survival difference between 
target therapy use after the reimbursement approval and non target therapy use 
before approval, HR = 0.073(0.031-0.176), p < 0.0001. The use of target therapy and 
non user was also significant with HR = 0.53(0.369-0.759), p = 0.0005. Multivariate 
Cox regression suggested that the effect of time gap in target therapy reimburse-
ment approval was statistical significant with p = 0.0019 ConClusions: Time gap 
due to reimbursement process influences patient’s mortality. Shortening the time 
gap to reimbursement approval is suggested.
PCN319
4+ years of amNog – CliNiCal Drivers for suCCessful Dossier 
suBmissioNs iN oNCology
Dehnen J, Goldhagen K, Petry D
IMS Consulting Group, Muenchen, Germany
objeCtives: 135 dossiers have been evaluated by G-BA since AMNOG was intro-
duced. Looking at oncology products, 43 have started into AMNOG process and for 
38 G-BA has finalized its decision. In 32 assessments an additional benefit was 
granted, leading to a success rate of 84% compared to only 36% in non-oncology 
products. Objective of this research is to identify drivers responsible for successful 
benefit assessment outcomes in oncology. Methods: All oncology assessments 
were analysed to reveal key drivers responsible for positive assessments by IQWiG 
+ G-BA. Next to comparator choice the analysis focused on submitted endpoints, 
where it is evaluated which endpoints contribute most in oncology indications 
to additional benefit. Results: Additional benefit is assessed based on patient 
relevant endpoints (mortality, morbidity, quality of life & safety). More than 55% 
of submitted endpoints fall in the safety category, followed by morbidity (approx. 
30%), mortality (approx. 10%) and quality of life (approx. 5%). OS has shown to be 
the most relevant endpoint, where the G-BA granted additional benefit in 23 out of 
32 dossiers primarily based on OS data. In terms of morbidity, PFS, ORR and “Time 
to Pain Progression” are the top three submitted morbidity endpoints; however, only 
“Time to Pain Progression” led to additional benefit in 2 out of 3 cases and QoL led 
to additional benefit in 4 cases. ConClusions: OS will continue to be the most 
relevant endpoint for IQWiG + G-BA when determining the additional benefit in 
oncology. In the absence of OS, PFS will not help in the overall additional benefit 
decision by G-BA, unless the MNF can justify PFS to be patient relevant according 
to IQWiG methodology. Although QoL is an accepted endpoint by G-BA, due to the 
high methodological standards set by G-BA and IQWiG chances are low that a QoL 
improvement alone will lead to additional benefit.
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ComParative Cost-effeCtiveNess of Drugs iN early versus late 
stages of CaNCer; review of the literature aND a Case stuDy iN 
Breast CaNCer
Dvortsin E1, Eijssen EM2, van Brussel J1, Gout-Zwart J1, Postma MJ2
1University of Groningen, Leeuwarden, The Netherlands, 2University of Groningen, Groningen, The 
Netherlands
objeCtives: Many oncological drugs that are being used in the adjuvant setting 
were first submitted for reimbursement in the metastatic stage, with differences 
in incremental cost-effectiveness ratios (ICERs) in both settings having potential 
implications for reimbursement and pricing. The aim of this study is to identify 
a possible trend in the cost-effectiveness for the early/adjuvant and late/meta-
static stages of oncological drugs through review and case study. Methods: We 
reviewed pairs of cost-effectiveness analyses of the same oncological drug in 
different stages for Scotland and the Netherlands. The case study in this report 
was directed at trastuzumab in the Dutch situation. Using a simplified Markov 
model, the cost-effectiveness in early and late stage of breast cancer was cal-
culated and compared to the findings from the review. Results: Comparable 
studies were found for cetuximab, bortezomib and bosutinib. Treatments in the 
late stage were found to be more expensive per QALY by a factor ranging from 
1.5 to 12. The case study provided a similar result; late stage treatment was more 
expensive by a factor 10. Using, for example, a threshold of € 80,000/QALY, the early 
stage of cetuximab, bosutinib and trastuzumab are deemed cost-effective, while 
their compared late stage is lifted over the threshold and potentially considered 
not cost-effective. ConClusions: ICERs of oncological drugs used in different 
stages are more unfavourable in the late stage than in the early stage. Applying 
a reasonable threshold may result in early stage treatment being deemed cost-
effective while late stage potentially not. Authorities should be aware of this when 
assessing oncological drugs and interpreting the corresponding ICERs, in the situ-
ation where oncological drugs are generally most submitted for reimbursement 
in the late stage initially.
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hta? the imPaCt of a limiteD eviDeNCe PaCkage
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